The synthetic, oxidized C-terminal fragment of the Plasmodium berghei circumsporozoite protein elicits a high protective response

European Journal of Immunology

Volumn 30, Issue 9, 2000, Pages 2679-2685

  Roggero, Mario A ^a   Meraldi, Valentin ^a   LÓpez, José A ^a   Eberl, Gérard ^a   Romero, Jackie C ^a   Matile, Hughe ^b   Betschart, Bruno ^c   Corradin, Giampietro ^a,d   Renggli, John ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c UNIVERSITY OF NEUCHÂTEL   (Switzerland)

^d Chemin des Croisettes 22   (Switzerland)

Author keywords

CTL; Parasite; Parasite immunity; Peptide; Vaccination

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE FRAGMENT; PROTOZOAL PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG ACTIVITY; IMMUNE RESPONSE; MOUSE; NONHUMAN; PARASITE IMMUNITY; PEPTIDE SYNTHESIS; PLASMODIUM BERGHEI; PRIORITY JOURNAL; SOLID PHASE EXTRACTION; SPOROZOITE; VACCINATION;

ANIMAL; FEMALE; IMMUNIZATION; INTERFERON TYPE II; MALARIA VACCINES; MICE; MICE, INBRED BALB C; OXIDATION-REDUCTION; PEPTIDE FRAGMENTS; PLASMODIUM BERGHEI; PROTOZOAN PROTEINS; SUPPORT, NON-U.S. GOV'T; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0033830013     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-4141(200009)30:9<2679::AID-IMMU2679>3.0.CO;2-#     Document Type: Article

References (30)

1. Rationale for the development of an engineered sporozoite malaria vaccine
2. + cells and malaria sporozoites
3. + cytolytic T cell clone confers protection against murine malaria
4. Malaria vaccine: Immunization of mice with a synthetic T cell helper epitope alone leads to protective immunity
5. + T cell- and IFN-gamma-dependent elimination of infected hepatocytes
6. + T cells and antibodies required for immunity to malaria sporozoites
7. + T lymphocytes is required for protective immunity against Plasmodium berghei
8. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria
9. A T cell clone directed at the circumsporozoite protein which protects mice against both Plasmodium yoelii and Plasmodium berghei
10. Elimination of P. berghei liver stages is not mediated by Fas (Apo-I) or perforin-dependent cytotoxicity
11. Development of antimalaria immunity in mice lacking IFN-gamma receptor
12. Synthesis and immunological characterization of 104-mer and 102-mer peptides corresponding to the N- and C-terminal regions of the Plasmodium falciparum CS protein
13. Recognition of synthetic 104-mer and 102-mer peptides corresponding to N- and C-terminal nonrepeat regions of the Plasmodium falciparum circumsporozoite protein by sera from human donors
14. Immunogenicity of synthetic peptides corresponding to the non-repeat regions of the Plasmodium falciparum circumsporozoite protein
15. Synthetic polypeptides corresponding to the non-repeat regions from the circumsporozoite protein of Plasmodium falciparum: Recognition by human T-cells and immunogenicity in owl monkeys
16. Elicitation of specific cytotoxic T cells by immunization with malaria soluble synthetic polypeptides
17. Extracellular processing and presentation of a 69-mer synthetic polypeptide to MHC class I-restricted T cells
18. H-2Kd-restricted antigenic peptides share a simple binding motif
19. The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of Plasmodium falciparum sporozoites
20. Structural and functional properties of region II-plus of the malaria circumsporozoite protein
21. + T-cell protective immunity induced by immunization with Plasmodium berghei CS protein-derived synthetic peptides: Evidence that localization of peptide-specific CTLs is crucial for protection against malaria
22. Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria
23. + T cell clones against Plasmodium yoelii liver stages
24. Protective efficacy against malaria of a combination sporozoite and erythrocytic stage vaccine
25. Peptides synthesis
26. Sequence of the circumsporozoite gene of Plasmodium berghei ANKA clone and NK65 strain
27. Liquid chromatographic determination of amino acids after gas-phase hydrolysis and derivatization with (dimethylamino)azobenzenesulfonyl chloride
28. Lymphoid cell surface interaction structures detected using cytolysis-inhibiting monoclonal antibodies
29. Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: Similarity of L3T4 to the human Leu-3/T4 molecule
30. Cellular response against exoerythrocytic forms of Plasmodium berghei in rats